# Antineoplastic agent.

## Abstract
The present invention relates to an antineoplastic agent containing a selenium compound of the general formula R₁ S R₂ X n wherein R₁ represents a halogen atom, a phenyl group, a lower alkoxy group or a halogen substituted lower alkoxy group, R₂ represents a halogen atom, a hydroxy group, a lower alkoxy group or a halogen substituted lower alkoxy group or R₁ and R₂ together form a group of the formula

## Claims
Claims 1. An antineoplastic agent containing a selenium compound of the general formula EMI18.1 wherein Rl represents a halogen atom, a phenyl group, a lower alkoxy group or a halogen substituted lower alkoxy group, R2 represents a halogen atom, a hydroxy group, a lower alkoxy group or a halogensubstituted lower alkoxy group or R1 and R2 together form a group of the formula EMI18.2 in which R3 and R4 each represent a hydrogen atom or a lower alkyl group , X represents pyridine, quinoline, isoquinoline or dioxane and n represents an integer of 0 to or Se Hal 4 Y m wherein Hal represents a halogen atom, Y represents pyridine and m represents 0 or 2. 2. An antineoplastic agent according to Claim 1 wherein Rl and R2 are each a chlorine atom or an ethoxy group or R1 and R2 together form a group EMI19.1 n n is 0 or 2 and X represents pyridine or quinoline. 3. An antineoplastic agent according to Claim l wherein Hal represents a chlorine or bromine atom and m represents 0 or 2. 4. An antineoplastic agent according to Claim l which contains a selenium oxychloride.pyridine 1 2 complex. 5. An antineoplastic agent according to Claim 1 which contains a selenium oxychloride.guinoline 1 2 complex. 6. An antineoplastic agent according to Claim I which contains diethyl selenite. 7. An antineoplastic agent according to Claim 1 which contains 1,2 ethanediol selenite. 8. An antineoplastic agent according to Claim 1 which contains selenium tetrachloride. 9. An antineoplastic agent according to Claim 1 which contains selenium tetrabromide. 10. An antineoplastic agent according to Claim 1 which contains a selenium tetrachloride pyridine lot2 complex. 11. A compound as defined in claim 1 for the treatment of tumors. 12. The use of a selenium compound of the following general formula for the preparation of antineoplastic agents EMI20.1 wherein R1 represents a halogen atom, a phenyl group, a lower alkoxy group or a halogen sub stituted lower alkoxy group, R2 represents a halogen atom, a hydroxy group, a lower alkoxy group or a halogen substituted lower alkoxy group or Rl and R2 together form a group of the formula EMI20.2 in which R3 and R4 each represent a hydrogen atom or a lower alkyl group , X represents pyridine, quinoline, isoquinoline or dioxane and n represents an integer of 0 to 2, or Se Hal 4 Y m wherein Hal represents a halogen atom, Y rep resents pyridine and m represents 0 or 2.

## Description
ANTINEOPLASTIC AGENTBackground of the Invention The methods of synthesis and some physicochemical properties of the selenium compounds of the present invention have already been known. However, medical properties such as an antineoplastic activity of them have not been reported yet. Malignant tumors have various properties and become resistant to antineoplastic agents after repeated use thereof. The development of new antineoplastic agents is, therefore, demanded.Summary of the Invention After intensive investigations of compounds having an antineoplastic effect, the inventors have found that selenium compounds of the following general formula have an antineoplastic effect EMI1.1 wherein R1 represents a halogen atom, a phenyl group, a lower alkoxy group or a halogen substituted lower alkoxy group, R2 represents a halogen atom, a hydroxy group, a lower alkoxy group or a halogen substituted lower alkoxy group or R1 and R2 together form a group of the formula EMI2.1 orEMI2.2 in which R3 and R4 each represent a hydrogen atom or a lower alkyl group , X represents pyridine, quinoline, isoquinoline or dioxane and n represents an integer of 0 to 2, or Se Hal 4 Y m II wherein Hal represents a halogen atom, Y represents pyridine and m represents 0 or 2. The present invention has been completed on the basis of this finding.Detailed Description of the Invention When R1 and R2 in the above general formula I are each a halogen atom, they may be fluorine, chlorine, bromine or iodine. Among them, chlorine or bromine is preferred. Examples of the lower alkoxy groups as R1 and R2 include methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec butoxy, t butoxy and pentyloxy groups. Among them, ethoxy and propoxy groups are preferred. The halogen substituted lower alkoxy groups are preferably chlorinated ones having 2 or 3 carbon atoms, such as 2 chloroethoxy and 2 chloropropoxy groups. When R1 and R2 are bonded together to form the above mentioned group, the lower alkyl group as R3 or R4 is, for example, a methyl group. Examples of the groups of the formula EMI3.1 formed by bonding R1 and R2 together includeEMI3.2 andEMI3.3 and examples of the groups of the formula EMI3.4 includeEMI3.5 EMI3.6 In a preferred combination of R1, R2, X X and n in the general formula I , R1 and R2 are each a chlorine atom or an ethoxy group or R1 and R2 are bonded together to formEMI3.7 wherein X is pyridine and n is 0 or In a preferred combination of Hal, Y and m in the general formula II , Hal is a chlorine or bromine atom, Y is pyridine and m is 0 or 2. typical examples of the compounds of the general formula I or II are as follows, which will be referred to as shown in the parentheses hereinafter 1. phenylseleninic acid, 2. ethyl phenylseleninate, 3. selenium oxychloride, SC 4. selenium oxychloridepyridine complex SCPY 5. selenium oxychloride quinoline complex SCQn 6. selenium oxychloride isoquinoline complex SCIQn 7. selenium oxychloride dioxane complex SCDX 8. selenium oxybromide.dioxane complex SBDX 9. diethyl selenite SOEt 10. di n propyl selenite SOPr 11. diisopropyl selenite SOIp 12. di 2 chloroethyl selenite SOCE 13. di 2 chloropropyl selenite SOCP 14. 1,2 ethanediol selenite SOEC 15. 1,2 propanediol selenite SOMEC 16. 2,3 butanediol selenite SODEC 17. 1,3 propanediol selenite SOPC 18 2,2 dimethyl 1,3 propanediol selenite SOMPC 19. selenium tetrachloride C4S 20. selenium tetrabromide B4S 21. selenium tetrachloride.pyridine complex C4SPy Among these compounds, those of Nos. 4, 5, 9, 14, 15, 16, 19, 20 and 21 are preferred. The phenylseleninic acid may be used in the form of its salt with sodium, potassium, ammonium or the like. A process for producing these compounds and ethyl phenylseleninate is described by G. Ayrey et.al. in J. Chem. Soc. 1962, 2089. A process for producing a complex of selenium oxychloride or selenium tetrachloride with pyridine is reported by B. Edgington J.B. Firth in J. Soc.Chem. Ind., 55, 192T 1936 . The molar ratio of selenium oxychloride to pyridine in this complex is either 1 1 or 1 2. Both are included in the scope of the present invention. A process for producing a complex of selenium oxychloride with quinoline or isoquinoline is reported by J. Jackson G.B.t. Smith in J. Am. Chem. Soc. 62, 544 1940 . The molar ratio of selenium oxychloride to quinoline or isoquinoline in this complex is either 1 1 or 1 2. Both are included in the scope of the present invention. A process for producing a complex of selenium oxychloride or selenium Qxybromide with dioxane, di 2 chloroethyl selenite and di 2 chloropropyl selenite is reported by N. N. Yarovenko et al. in Zh. Obshch. Khim. 31, 4006 1961 . A process for producing diethyl selenite, di n p ropyl selenite and diisopropyl selenite is reported by F. Ando et al. in Bull, Chem. Soc. Jpn. 52, 807 1979 . A process for producing 1,2 ethanediol selenite and 2,2 dimethyl 1,3 propanediol selenite is reporated by D. B. Denney et al. in J. Am. Chem. Soc. 103, 2340 1981 . A process for producing 1,2 propanediol selenite, 2,3 butanediol selenite and 1,3 propanediol selenite is reporated by R. C. Mehrotra S. N. Mathur in J.Indian. Chem. Soc. 42, 814 1965 . A process for producing selenium oxychloride is reporated by Drago Whitten in Inorg. Chem. 5, 677 1966 . A process for producing selenium tetrachloride is reported by Lamb in Am. Chem. J. 30, 209 1903 . A process for producing selenium tetrabromide is reported by Pogg in Ann. 128, 327 1866 . The antineoplastic agent of the present invention can be formulated and administered by various known methods. The methods of administration in clude, for example, injection, oral and rectal administration. The forms of the preparation include injection, powder, granules, tablets and suppositories. In the formulation, medical additives such as carriers, excipients, stabilizers, antiseptics, soothing agents and emulsifiers may be used if necessary so far as they do not exert an adverse effect on the selenium compound. Examples of the excipients and stabilizers include mannitol, lactose, maltose, dextran, starch and polyethylene glycol. Examples of the antiseptics include benzalkonium chloride, benzyl alcohol and parabens. Examples of the soothing agents include benzyl alcohol, inositol and glucose. Examples of the emulsifiers include polysorbates and fatty acid esters. Examples of the base materials for the suppositories include fatty acid triglycerides, polyethylene glycol and polyvinyl alcohol. The amount of the selenium compound in the antineoplastic agent which is variable over a wide range depending on the form of the antineoplastic agent is generally 0.01 to 100 wt. , preferably 0.1 to 70 wt. and the balance comprises ordinary medicinal carrier and other additives. An effective dose of the antineoplastic agent of the present invention in the above mentioned form is applied to the patients. The dosages determined on the basis of the results of basic experiments of pharmacological effects are 0.01 to 10 mg kg day, preferably 0.1 to 2 mg kg day in the oral administration, 0.01 to 5 mg kg day, preferably 0.1 to 1 mg kg day for the injection and 0.01 to 10 mg kg day, preferably 0.1 to 2 mg kg day for the suppositories. The antineoplastic effect of the selenium compounds of the present invention will be shown by the following experiments Experiment 1 Effect of inhibiting the proliferation of incubated Hela S3 cells Sample Selenium oxychloride.pyridine 1 1 complex was used as the sample. Method of experiment Hela S3 cells were placed on a culture medium NEM containing 10 of calf serum in a plastic dish.After 2 days, an organoselenium compound was added thereto. After containing the culture for additional 3 days, the number of the cells was counted. The proliferation inhibition rate was calculated according to the following formula Inhibition rate l00 x B A B C in which A is the final number of the cells counted on the third day after addition of the test sample, B is the final number of the cells in a sample free control and C is the number of the cells counted immediately after the addition of the test sample.The value of IC50 50 inhibitory concentration was determined from a graph showing the relationship between the concentration of the sample and the inhibition rate. Results of experiment The results were as follows Compound ICso pg ml Selenium oxychloridepyridine 0.59 1 1 complexExperiment 2 Antineoplastic effect on Ehrlich carcinoma Compounds shown in Tables 1 and 2 were used as the samples Table 1EMI10.1 EMI10.2 tb No SEP Abbreviated SEP R1 SEP R SEP n SEP x tb SEP name SEP 1 SEP 2 tb 1 SEP SEP OH SEP o tb 2 SEP 5 SEP OC2H5 SEP O tb 3 SEP SC SEP Cl SEP Cl SEP 0 tb 4. SEP SCPY SEP Cl SEP Cl SEP 2 tb 5 SEP SCOn. SEP Cl SEP Cl SEP 2 SEP X tb 6 SEP SCIOn SEP Cl SEP Cl SEP 2 SEP X tb 7 SEP SCDX SEP Cl SEP Cl SEP 1 SEP G tb 8 SEP SBDX SEP Br SEP Br SEP 1 SEP 0 SEP 0 tb 9 SEP SOET SEP 0C2H5 SEP OC2H5 SEP 0 tb 10 SEP SOPr SEP O CH2CH2CH3 SEP OCH2CH2CH3 SEP 0 tb 11 SEP SOIP SEP O CH SEP SEP CH3 SEP O CH SEP CH3 SEP 0 tb NCH3 SEP SEP CH3 tb EMI11.1 tb 12 SEP SOCE SEP oCH2CH2Cl SEP OCH2CH2Cl SEP 0 SEP tb 13 SEP SOCP SEP OCH2CHClCH3 SEP OCH2CHClCH3 SEP 0 SEP tb SEP H3 SEP SEP CHj SEP 0 tb 14 SEP SOEC SEP O SEP o SEP o tb SEP CH2 SEP SEP CH tb SEP CH2 tb 15 SEP SOMEC SEP O SEP 0 SEP 0 SEP 15 SEP SOMsC SEP o SEP o SEP o tb SEP CH2 SEP SEP CH tb SEP CH3 tb 16 SEP SODEC SEP O SEP 0 SEP 0 SEP tb SEP CH SEP SEP CH tb SEP eH3 tb SEP CH3 SEP CH3 tb 17 SEP SOPC SEP O0 tb SEP CH2 SEP SEP CH2 tb SEP CH2 tb 18 SEP SOMPC SEP 0 SEP 0 SEP 0 SEP tb SEP I SEP I tb SEP CM, SEP CHO tb SEP C tb SEP CH3 SEP CH3 tb SEP 3 SEP 3 tb Table 2 Se Hal 4. Y m EMI12.1 tb No. SEP IIal SEP m SEP Y tb SEP .nwre tb 19 SEP C4S SEP Cl SEP 0 SEP tb 20 SEP B4S SEP Br SEP 0 SEP tb 21 SEP C4SPY SEP Cl SEP 2 tb method of experiment About 106 0.2 ml of Ehrlich carcinoma cells were placed in an abdomen of each male ICR mouse of 5 weeks old. On the next day the administration of the test sample in the abdomen was started. The test sample was given once a day for 7 days. For an untreated group, a physiological saline solution was given in the same manner as above. After the administration, the mice were observed for 30 days.The T C percent T C x 100 was determined from the average survival periods days of the treated group and control group. Further, 50 lethal dose LD50 was determined from the number of the mice which died of tonicity of the test samples administered. The results are shown in Table 3. Table 3Compound Observation Antineoplastic effect dose mg kg LD50No. period days 0.5 0.75 1.0 1.5 2.0 3.0 4.0 6.0 8.0 16.0 32.0 64.0 mg kg dayx7 1 30 122.6 128.6 141.4 148.9 16 60 123 129 141 149 2 30 117.7 133.8 150.0 87.9 16 32 60 118 134 193 88 3 60 141 122 168 105 6 4 30 178.6 188.1 200.8 77.0 8 16 60 218 270 297 95 5 30 131.4 156.0 181.8 174.2 16 60 131 199 269 235 6 30 158.5 164.8 162.9 77.4 8 16 60 211 206 187 77 7 60 211 225 194 40 8 16 8 60 182 226 228 78 8 16 cont d Table 3Compound Observation Antineoplastic effect dose mg kg LD50No. period days 0.5 0.75 1.0 1.5 2.0 3.0 4.0 6.0 8.0 16.0 32.0 64.0 mg kg dayx7 9 60 246 203 201 14 4 8 10 60 175 170 102 14 8 11 60 204 236 126 14 4 8 12 60 197 225 194 65 8 13 60 190 234 219 71 8 16 14 60 193 266 108 34 4 8 15 60 227 258 204 105 8 16 60 185 216 261 174 8 17 60 174 221 197 83 4 8 18 60 164 193 194 194 8 19 60 167 179 249 183 16 20 60 196 272 183 56 8 16 21 60 155 217 246 101 8 16 It is apparent from Table 3 that all the test compounds had a remarkable life prolonging effect.Experiment 3 Antimutagenic properties Method of experiment The experiment was carried out by Ames method using Salmonella typhimurium TA 98 hereinafter referred to as TA 98 as the test microorganism and benzofa pyrene hereinafter referred to as B a P as the mutagen. 0.1 ml of a solution containing 5 pg of B a P and a suitable amount of a compound of the present invention was added to 0.5 ml of S 9 mix and 0.1 ml of a TA 98 suspension. The mixture was incubated at 37 C for 20 min. 2 ml of soft agar was added thereto, mixed well and then spread evenly on a glucose minimum agar medium plate. After the incubation at 370C for 48 h, the number of colonies formed by the back mutation was counted. The number of the colonies formed when neitherB a P nor the compound of the present invention was used was employed as the background. The antimutagenic properties was shown as the rate of inhibition of the mutagenic effect according to the following formula inhibition rate EMI16.1 tb SEP number SEP of SEP colonies SEP formed tb SEP when SEP the SEP compound SEP of SEP the SEP I SEP SEP groun SEP d SEP tb SEP SEP invention SEP was SEP used SEP SEP tb SEP 1 SEP SEP x SEP 100 tb SEP number SEP of SEP colonies SEP formed tb SEP when SEP the SEP compound SEP of SEP the SEP back tb SEP invention SEP was SEP not SEP used SEP ground tb The results are shown in Table 4. Table 4Compound dose g plate No. back ground 0 0.5 1 5 10 50 100 500 Nurriber of 28 272 213 192 1 30 144 93 87 41 4 colonies inhibi tion rate 0 23.0 32.8 37.7 52.5 73.4 75.8 94.7 Number of 25 293 231 235 156 145 76 62 32 14 colonies inhibi tion rate 0 23.1 21.6 51.1 55.2 81.0 86.2 97.4 Number of 32 286 205 230 154 132 72 70 27 colonies inhibi tion rate 0 30.3 22.0 52.0 60.6 84.3 85.6 100 It is apparent from Table 4 that all the test compounds exhibited antimutagenic properties. Effects As described above in detail, all the selenium compounds used in the present invention have a remark able life prolonging effect on mice bearing cancer and antimutagenic effect to bacteria. Thus, the use of them as antineoplastic agents is expected. The following examples will show preparations of the antineoplastic agents of the present invention.Preparation Example l One g of selenium oxychloride.guinoline 1 2 complex was dissolved in 200 ml of a physiological saline solution. The solution was filtered through a Millipore filter GS to remove microbes. Two ml of the filtrate was placed in a 10 ml ampoule and freeze dried to obtain an injection containing 10 mg of the antineoplastic agent.Preparation Example 2 Ten parts by weight of phenylseleninic acid, 120 parts of crystalline lactose, 167 parts of crystalline cellulose and 3 parts of magnesium stearate were mixed together in a V type mixer and then shaped into tablets each containing 100 mg of the active ingredient with a tableting machine.